Compare BY & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | BBOT |
|---|---|---|
| Founded | 1914 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2017 | N/A |
| Metric | BY | BBOT |
|---|---|---|
| Price | $29.21 | $13.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.67 | $23.80 |
| AVG Volume (30 Days) | ★ 197.2K | 168.9K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 1.54 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $400,663,000.00 | N/A |
| Revenue This Year | $19.26 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $10.42 | ★ N/A |
| Revenue Growth | ★ 7.23 | N/A |
| 52 Week Low | $22.63 | $8.50 |
| 52 Week High | $32.05 | $14.78 |
| Indicator | BY | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | N/A |
| Support Level | $27.82 | N/A |
| Resistance Level | $28.45 | N/A |
| Average True Range (ATR) | 0.55 | 0.00 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 90.54 | 0.00 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.